Vivos in the News
-
- News
April 3, 2026Eli Lilly’s Centessa Purchase at Nearly $8 Billion Makes VVOS the Most Undervalued Nasdaq Company
Eli Lilly just agreed to pay up to $7.8 billion for a sleep-drug company with no approved products and years from commercialization—while a publicly traded company already treating thousands of… -
- News
March 18, 2026Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Vivos CARE Oral Medical Devices Proven to Enhance Airways by Redeveloping Dental Arch Forms and Jaws LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the… -
- News
February 9, 2026Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’)… -
- News
January 16, 2026Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing… -
- News
January 9, 2026Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep Solutions LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’)… -
- Blog
- |
- News
November 19, 2025Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
November 19, 2025 16:20 ET | Source: Vivos Therapeutics, Inc Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center…
